Literature DB >> 2154440

In-vitro activity of azithromycin against Chlamydia trachomatis.

C Scieux1, A Bianchi, B Chappey, I Vassias, Y Pérol.   

Abstract

We evaluated the efficacy of azithromycin, erythromycin and doxycycline in controlling in-vitro propagation of Chlamydia trachomatis in HeLa 229 cells. Eight recent clinical isolates of C. trachomatis and two fast-growing strains were tested with inocula of 10(3)-10(5) inclusion forming units per well of a 96-well microtitre plate. C. trachomatis inclusions were detected by an immunoperoxidase-antiperoxidase procedure (PAP), including a genus-specific monoclonal antibody. MIC ranges were 0.064-0.25 mg/l azithromycin, 0.064-0.128 mg/l erythromycin and 0.016-0.064 mg/l doxycyline; MBC ranges were 2-8 mg/l azithromycin, 4-64 mg/l erythromycin and 0.5-8 mg/l doxycycline. Since azithromycin appears to be effective against C. trachomatis, clinical studies in sexually transmitted diseases are indicated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154440     DOI: 10.1093/jac/25.suppl_a.7

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae.

Authors:  M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  Concentration of azithromycin in human prostatic tissue.

Authors:  G Foulds; P Madsen; C Cox; R Shepard; R Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 3.  Ocular Chlamydia trachomatis infection: elimination with mass drug administration.

Authors:  Meraf A Wolle; Sheila K West
Journal:  Expert Rev Anti Infect Ther       Date:  2019-02-18       Impact factor: 5.091

4.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

5.  Azithromycin levels in cervical mucus and plasma after a single 1.0g oral dose for chlamydial cervicitis.

Authors:  A M Worm; A Osterlind
Journal:  Genitourin Med       Date:  1995-08

6.  Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis.

Authors:  J M Ossewaarde; F H Plantema; M Rieffe; R P Nawrocki; A de Vries; A M van Loon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

7.  A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males.

Authors:  A Nilsen; A Halsos; A Johansen; E Hansen; E Tørud; D Moseng; G Anestad; G Størvold
Journal:  Genitourin Med       Date:  1992-10

Review 8.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

9.  In vitro activity of dirithromycin against Chlamydia trachomatis.

Authors:  J Segreti; K S Kapell
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin.

Authors:  A S Beale; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.